Umapathysivam, M. M., Araldi, E., Hastoy, B., Dawed, A. Y., Vatandaslar, H., Mayrhofer, J. E., . . . Gloyn, A. L. (2026). Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists. Umapathysivam, M M, Araldi, E, Hastoy, B, Dawed, A Y, Vatandaslar, H, Mayrhofer, J E, Lindquist, P, Silva, P N, Goga, A, Trüllinger, G O, Godbersen, S, Sengupta, S, Kaufmann, A, Thomsen, S K, Hartmann, B, Chen, Y C, Jonsson, A E, Kabakci, H, Thaman, S, Grarup, N, Have, C T, Pallo, L P, Faerch, K, Gjesing, A P, Nawaz, S, Cheeseman, J, Neville, M J, Pedersen, O, Walker, M, Sun, H, Jennison, C, Hattersley, A T, Rehfeld, J F, Holman, R R, Verchere, B C, Hansen, T, Karpe, F, Holst, J J, Rosenkilde, M M, Jones, A G, Ristow, M, McCarthy, M I, Pearson, E R, Stoffel, M & Gloyn, A L 2026, 'Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists', Genome Medicine, vol. 18, no. 1, 40. https://doi.org/10.1186/s13073-026-01630-0. https://doi.org/10.1186/s13073-026-01630-0
Παραπομπή σε μορφή Chicago (17η εκδ.)Umapathysivam, Mahesh M., et al. "Type 2 Diabetes Risk Alleles in Peptidyl-glycine Alpha-amidating Monooxygenase Influence GLP-1 Levels and Response to GLP-1 Receptor Agonists." Umapathysivam, M M, Araldi, E, Hastoy, B, Dawed, A Y, Vatandaslar, H, Mayrhofer, J E, Lindquist, P, Silva, P N, Goga, A, Trüllinger, G O, Godbersen, S, Sengupta, S, Kaufmann, A, Thomsen, S K, Hartmann, B, Chen, Y C, Jonsson, A E, Kabakci, H, Thaman, S, Grarup, N, Have, C T, Pallo, L P, Faerch, K, Gjesing, A P, Nawaz, S, Cheeseman, J, Neville, M J, Pedersen, O, Walker, M, Sun, H, Jennison, C, Hattersley, A T, Rehfeld, J F, Holman, R R, Verchere, B C, Hansen, T, Karpe, F, Holst, J J, Rosenkilde, M M, Jones, A G, Ristow, M, McCarthy, M I, Pearson, E R, Stoffel, M & Gloyn, A L 2026, 'Type 2 Diabetes Risk Alleles in Peptidyl-glycine Alpha-amidating Monooxygenase Influence GLP-1 Levels and Response to GLP-1 Receptor Agonists', Genome Medicine, Vol. 18, No. 1, 40. Https://doi.org/10.1186/s13073-026-01630-0 2026. https://doi.org/10.1186/s13073-026-01630-0.
Παραπομπή σε μορφή MLA (9th εκδ.)Umapathysivam, Mahesh M., et al. "Type 2 Diabetes Risk Alleles in Peptidyl-glycine Alpha-amidating Monooxygenase Influence GLP-1 Levels and Response to GLP-1 Receptor Agonists." Umapathysivam, M M, Araldi, E, Hastoy, B, Dawed, A Y, Vatandaslar, H, Mayrhofer, J E, Lindquist, P, Silva, P N, Goga, A, Trüllinger, G O, Godbersen, S, Sengupta, S, Kaufmann, A, Thomsen, S K, Hartmann, B, Chen, Y C, Jonsson, A E, Kabakci, H, Thaman, S, Grarup, N, Have, C T, Pallo, L P, Faerch, K, Gjesing, A P, Nawaz, S, Cheeseman, J, Neville, M J, Pedersen, O, Walker, M, Sun, H, Jennison, C, Hattersley, A T, Rehfeld, J F, Holman, R R, Verchere, B C, Hansen, T, Karpe, F, Holst, J J, Rosenkilde, M M, Jones, A G, Ristow, M, McCarthy, M I, Pearson, E R, Stoffel, M & Gloyn, A L 2026, 'Type 2 Diabetes Risk Alleles in Peptidyl-glycine Alpha-amidating Monooxygenase Influence GLP-1 Levels and Response to GLP-1 Receptor Agonists', Genome Medicine, Vol. 18, No. 1, 40. Https://doi.org/10.1186/s13073-026-01630-0, 2026, https://doi.org/10.1186/s13073-026-01630-0.